PP
ATXS

Paloma Partners’s Astria Therapeutics ATXS Stock Holding History

Paloma Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-355
Closed -$79K – 1828
2016
Q2 		$79K Buy
+355
New +$107K ﹤0.01% 2087

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paloma Partners's ATXS Position: Q3 2016 in Review

Paloma Partners sold out of Astria Therapeutics (ATXS) in Q3 2016, closing a stake of 355 shares — an estimated $79K sold.

Paloma Partners first reported a position in ATXS in Q2 2016 and held it in 1 quarter. The position peaked at $79K in Q2 2016. 31 funds tracked by Wall St. Rank hold ATXS as of Q3 2016.

  • Paloma Partners reported no remaining Astria Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Paloma Partners sold 355 Astria Therapeutics shares in Q3 2016, an estimated $79K.
  • Paloma Partners first reported a position in Astria Therapeutics in Q2 2016 and held it in 1 quarter.
  • Paloma Partners's Astria Therapeutics position peaked at $79K in Q2 2016.
  • 31 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2016.

Based on Paloma Partners's 13F filing for Q3 2016, filed 14 Nov 2016.